FNArena Windows
Introduction to FNArena Windows
FNArena Windows offers subscribers the option to investigate ASX-listed stocks against their peers. FNArena developed its own sector methodology which in our view overcomes many flaws and disadvantages connected with GICS sectors. Our system starts with three broad sector labels: COMMODITIES, FINANCIAL SERVICES and INDUSTRIALS. From here onwards subscribers can explore further through gradually narrowing branches. This is not investment advice, but simply another window on the Australian Stock Exchange to provide better insight and to assist FNArena subscribers while conducting their own market analysis.
| ASX CODE | LAST PRICE | % MOVE | 52WK HIGH | 52WK LOW | P/E | CONSENSUS TARGET | UPSIDE/DOWNSIDE |
|---|---|---|---|---|---|---|---|
| CLV | $0.92 |
|
$1.17 | $0.53 |
|
||
| EBO | $17.41 |
|
$30.44 | $15.68 | 14.3 |
$23.81 |
|
| EXL | $0.01 | 0.00% | $0.02 | $0.01 |
|
||
| MCP | $0.13 | 0.00% | $0.28 | $0.12 |
|
||
| SIG | $2.69 |
|
$3.20 | $2.58 | 38.2 |
$3.163 |
|
| SK1 | $2.58 |
|
$2.96 | $2.13 | 23.5 |
$2.90 |
|
-6.15% 
36.8% Previous Stories
The Monday Report
Mar 22 2010
A wrap of events affecting the market on Friday night and the weekend and a preview of the week ahead.
API Surprises, But Brokers Non-Enthusiastic
Oct 22 2009
Most Australian stockbrokers simply cannot get excited about Australian Pharmaceutical Industries.
Generic Margins Remain The Issue For Sigma
Sep 15 2009
Brokers were generally nonplussed by the Sigma Pharmaceuticals interim result as margins in the generic business remain a concern and an impediment to group earnings growth.
Stockbrokers Cannot Get Excited About Sigma
Sep 08 2009
Sigma Pharmaceuticals has acquired 15 brands plus a manufacturing facility from BMS and announced a rights issue.
Playing The Lipstick Indicator
Oct 31 2008
Why might Australian Pharmaceutical rejoice in the Lipstick Indicator, and what might this have to do with Downer EDI?
Sigma Struggling With FY Forecasts
Sep 23 2008
Sigma Pharmaceuticals’ first half profit was lower than expected, leading brokers to predict the company will do it tough in meeting its full year targets.